ReviewJournal of cardiovascular translational research2026
A Hidden Indicator of Cardiovascular Health: Serum Gamma-Glutamyl Transferase in Focus.
Review in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutathione, a critical component of cellular antioxidant defences, is metabolized by gamma-glutamyl transferase (GGT), an enzyme increasingly recognized for its role in cardiovascular diseases (CVD). Elevated GGT levels have been associated with a heightened risk of conditions such as heart failure, coronary artery disease, acute coronary events, and adverse cardiovascular outcomes. This study aims to evaluate the role of serum GGT as a cardiac marker for detecting various cardiac diseases and its potential utility in clinical practice. Elevated GGT correlates with several CVD risk factors, including diabetes, hypertension, and metabolic syndrome, and is associated with acute coronary syndromes and myocardial infarction. The study results suggest that serum GGT is a promising biomarker for cardiovascular risk prediction, aiding in the assessment of disease severity and prognosis. GGT has the potential to play a pivotal role in preventive cardiology and personalized medicine, contributing to improved outcomes for patients with CVD.
Indexed as
Identifiers
42257817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.